Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD4 | P21917 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL554231 | 0.94 | HTT (0.41) | HTTCYP3A4SMN1; SMN2SMYD2DRD2 | |
| SCHEMBL31682488 | 0.91 | KDM4E (0.41) | HTTCYP3A4SMN1; SMN2SIGMAR1DRD2 | |
| SCHEMBL553453 | 0.89 | HTT (0.51) | HTR1BHTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL29135908 | 0.88 | SIGMAR1 (0.45) | HTTSIGMAR1DRD2DRD4DRD3 | |
| SCHEMBL31704177 | 0.86 | ALDH1A1 (0.42) | HTR1BHTTCYP3A4SMN1; SMN2 | |
| SCHEMBL20954569 | 0.84 | SIGMAR1 (0.43) | HTTCYP3A4SMN1; SMN2SMYD2SIGMAR1 | |
| SCHEMBL706843 | 0.83 | SMYD2 (0.40) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL4398294 | 0.82 | ALDH1A1 (0.42) | DRD2DRD4DRD3 | |
| SCHEMBL31618578 | 0.82 | LTA4H (0.42) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL553963 | 0.82 | HTR1B (0.46) | HTR1BHTTCYP3A4SMN1; SMN2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | HTR1B 2686/4885HTT 3192/4885CYP3A4 1309/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTR1B 2686/4885HTT 3192/4885CYP3A4 1309/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTR1B 2686/4885HTT 3192/4885CYP3A4 1309/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | HTR1B 3542/4885HTT 3761/4885CYP3A4 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.